MX2023003170A - Moduladores de la caseina cinasa 1 delta. - Google Patents

Moduladores de la caseina cinasa 1 delta.

Info

Publication number
MX2023003170A
MX2023003170A MX2023003170A MX2023003170A MX2023003170A MX 2023003170 A MX2023003170 A MX 2023003170A MX 2023003170 A MX2023003170 A MX 2023003170A MX 2023003170 A MX2023003170 A MX 2023003170A MX 2023003170 A MX2023003170 A MX 2023003170A
Authority
MX
Mexico
Prior art keywords
sup
casein kinase
methods
disorders
delta modulators
Prior art date
Application number
MX2023003170A
Other languages
English (en)
Inventor
Wei Zhang
Brock T Shireman
Terry Patrick Lebold
Dongpei Wu
Mark Seierstad
Kelly J Mcclure
Stefan Mccarver
Cathy Preville
Jocelyn Wang
Jeannie Ziff
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023003170A publication Critical patent/MX2023003170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un compuesto de Fórmula (I) o Fórmula (II), composiciones farmacéuticas que los contienen, métodos para prepararlos y métodos para utilizarlos, que incluyen métodos para tratar patologías, trastornos y afecciones asociados con la modulación de la caseína cinasa 1 delta (CSNK1D), tales como los asociados con trastornos psiquiátricos/del estado de ánimo, enfermedades neurodegenerativas, cánceres, trastornos de adicción y abuso de sustancias, dolor y enfermedades metabólicas.(ver Fórmulas) En donde R1, R2, R3, R4, R1a, R2a, R3 y R4a se definen en el presente documento.
MX2023003170A 2020-09-17 2021-09-16 Moduladores de la caseina cinasa 1 delta. MX2023003170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063079812P 2020-09-17 2020-09-17
PCT/IB2021/058447 WO2022058921A1 (en) 2020-09-17 2021-09-16 Casein kinase 1 delta modulators

Publications (1)

Publication Number Publication Date
MX2023003170A true MX2023003170A (es) 2023-03-27

Family

ID=78087415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003170A MX2023003170A (es) 2020-09-17 2021-09-16 Moduladores de la caseina cinasa 1 delta.

Country Status (9)

Country Link
US (1) US20230339900A1 (es)
EP (1) EP4214199A1 (es)
JP (1) JP2023541463A (es)
KR (1) KR20230069169A (es)
CN (1) CN116490503A (es)
AU (1) AU2021345564A1 (es)
CA (1) CA3189703A1 (es)
MX (1) MX2023003170A (es)
WO (1) WO2022058921A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CN104906103B (zh) * 2010-12-14 2018-05-18 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
AU2011346733C1 (en) * 2010-12-20 2015-12-24 Biogen Ma Inc. Novel fused pyridine compounds as casein kinase inhibitors
MX2019009083A (es) * 2017-02-01 2019-09-10 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cancer.

Also Published As

Publication number Publication date
KR20230069169A (ko) 2023-05-18
CN116490503A (zh) 2023-07-25
US20230339900A1 (en) 2023-10-26
EP4214199A1 (en) 2023-07-26
JP2023541463A (ja) 2023-10-02
WO2022058921A1 (en) 2022-03-24
AU2021345564A1 (en) 2023-06-01
CA3189703A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
CR20210153A (es) Moduladores de monoacilglicerol lipasa
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
DE60037139D1 (de) Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
AP2003002825A0 (en) Pyrazole compounds useful as protein kinase inhibitors
PT1613315E (pt) Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias
YU23202A (sh) Lekovi za tretman malignih tumora
JO2629B1 (en) Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
MX2023003165A (es) Moduladores de la caseína cinasa 1 delta.
BRPI0509515A (pt) composto, formulação farmacêutica, uso de um composto método para tratamento de doenças, e, processo para a preparação de um composto
AP2003002801A0 (en) Benzothiophene derivative compounds, process of preparation and use thereof
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
CR20220376A (es) Moduladores de la monoacilglicerol lipasa
MX2022011901A (es) Arilo piperidinas como moduladores de monoacilglicerol lipasa.
MX2022011903A (es) Azaspirociclos como moduladores de monoacilglicerol lipasa.
CR20220068A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
MX2022011904A (es) Aminociclobutanos como moduladores de monoacilglicerol lipasa.
MX2022011902A (es) Moduladores de la monoacilglicerol lipasa.
MX2021003661A (es) Moduladores de la monoacilglicerol lipasa.
MX2023008589A (es) Compuestos moduladores de gcn2 y usos de los mismos.
MX2023003170A (es) Moduladores de la caseina cinasa 1 delta.
MX2023006751A (es) Nuevo derivado de camptotecina, composicion que comprende el mismo y su uso.
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.